Vanda Pharmaceuticals is spending big on R&D. Here’s what it has on tap for 2023.


The D.C. biotech is looking to new areas of treatment to drive its next phase of growth.

Previous Tech firm and health care disrupter ShiftKey rises to top of SMU's Dallas 100
Next Surface Oncology lays off one-fifth of staff as it stops work on drug